trending Market Intelligence /marketintelligence/en/news-insights/trending/XBt_6CJ7FswvHqV7i1oz3Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

UK price watchdog rejects Akcea's rare disease drug in draft guidance

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


UK price watchdog rejects Akcea's rare disease drug in draft guidance

The U.K. National Institute for Health and Care Excellence said Akcea Therapeutics Inc.'s volanesorsen was not a cost-effective treatment for patients with familial chylomicronemia syndrome.

Familial chylomicronemia syndrome, or FCS, is a rare genetic disease that prevents the body from breaking down fats, causing abdominal pain and unpredictable and recurrent episodes of acute pancreatitis. The condition is estimated to affect between 55 and 110 people in England.

In a draft guidance, the health cost watchdog said that while the medicine showed some benefit in the short term, there was a lack of evidence in whether it continued to work over a longer period. Furthermore, there was uncertainty about the drug because the company's application described a different dose than the one used in its main clinical trials.

The agency also raised pricing concerns, saying the drug's cost-effectiveness estimates were higher than what it normally considers to be an acceptable use of the country's National Health Service resources.

Volanesorsen, a self-administered injection designed to treat FCS, is also called Waylivra. It was approved across Europe in 2019.

Akcea Therapeutics is a unit of Ionis Pharmaceuticals Inc.